BioMedNewsBreaks — Safety Shot Inc. (NASDAQ: SHOT) Receives Notice of Allowance for US Patent Covering Newest Formula for ‘Making People Feel Better Faster’

Posted

Safety Shot (NASDAQ: SHOT), a wellness and dietary supplement company, is announcing the Notice of Allowance for a U.S. patent. The patent covers the company’s newest clinically backed formula to solve alcohol related problems. According to the announcement, Safety Shot’s family of patents is intended to support its competitive advantage in the market which includes being faster at removing alcohol, enhancing cognitive ability, and reducing impairment by aiding the metabolism of alcohol.

“This latest patent marks a significant milestone in Safety Shot’s quest to lead a brand-new category that the company has created to solve alcohol related problems,” said Safety Shot COO and co-owner of the patent, David Sandler. “The patent locks up our IP and further separates us from the pack as the only group that has been able to prove that Safety Shot’s revolutionary formula can dramatically reduce blood alcohol and reduce the build-up toxins associated with alcohol consumption rapidly. This patent helps solidify Safety Shot as the uncontested world leader in making people feel better faster.”

To view the full press release, visit https://ibn.fm/nJWfg

About Safety Shot Inc.

Safety Shot, a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness beverage on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for retail purchase online at www.DrinkSafetyShot.com and www.Amazon.com. The company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024. For more information about the company, visit www.SafetyShotHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to SHOT are available in the company’s newsroom at https://ibn.fm/SHOT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN